-
Global Hunter Securities Comments On Taracept Announcement
Friday, March 25, 2011 - 7:13am | 143Read More...According to Global Hunter Securities, Targacept (NYSE: TRGT) announced that top-line Phase II TC-5619 data in patients with attention deficit/hyperactivity disorder (ADHD) did not meet the primary efficacy outcome measure. Global Hunter Securities reported that while there was an absence of...
-
Hapoalim Securities Raises TRGT Target To $28 From $25
Friday, February 11, 2011 - 8:39am | 23Read More...Hapoalim Securities is raising its PT on shares of Targacept, Inc. (NASDAQ: TRGT) to $28 from $25.
